anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Arsenic trioxide was investigated in Study PLRXAS01, an open-label, single-arm trial in 40 patients with relapsed or refractory APL who were previously treated with an anthracycline and a retinoid regimen. Patients received arsenic trioxide 0.15 mg/kg/day intravenously over 1 to 2 hours until the bone marrow was cleared of leukemic cells or for a maximum of 60 days. The CR (absence of visible leukemic cells in bone marrow and peripheral recovery of platelets and white blood cells with a confirmatory bone marrow ≥ 30 days later) rate in this population of previously treated patients was 28 of 40 (70%). Among the 22 patients who had relapsed less than one year after treatment with tretinoin, there were 18 complete responders (82%). Of the 18 patients receiving arsenic trioxide ≥ one year from tretinoin treatment, there were 10 complete responders (55%). The median time to bone marrow remission was 44 days and to onset of CR was 53 days. Three of 5 children, 5 years or older, achieved CR. No children less than 5 years old were treated.

Three to six weeks following bone marrow remission, 31 patients received consolidation therapy with arsenic trioxide, at the same dose, for 25 additional days over a period up to 5 weeks. In follow-up treatment, 18 patients received further arsenic trioxide as a maintenance course. Fifteen patients had bone marrow transplants. At last follow-up, 27 of 40 patients were alive with a median follow-up time of 484 days (range 280 to 755) and 23 of 40 patients remained in complete response with a median follow-up time of 483 days (range 280 to 755). 

Cytogenetic conversion to no detection of the APL chromosome rearrangement was observed in 24 of 28 (86%) patients who met the response criteria defined above, in 5 of 5 (100%) patients who met some, but not all, of the response criteria, and 3 of 7 (43%) of patients who did not respond. RT-PCR conversions to no detection of the APL gene rearrangement were demonstrated in 22 of 28 (79%) of patients who met the response criteria, in 3 of 5 (60%) of patients who met some, but not all, of the response criteria, and in 2 of 7 (29%) of patients who did not respond.

Responses were seen across all age groups tested, ranging from 6 to 72 years. The ability to achieve a CR was similar for both sexes. There were insufficient patients of Black, Hispanic, or Asian ancestry to estimate relative response rates in these groups, but responses were seen in each group.
The median sc lethal dose of terbutaline sulfate in mature rats was approximately 165 mg/kg (approximately 2,700 times the maximum recommended daily sc dose for adults on a mg/m2 basis). The median sc lethal dose of terbutaline sulfate in young rats was approximately 2,000 mg/kg (approximately 32,000 times the maximum recommended daily sc dose for adults on a mg/m2 basis).

The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Hypokalemia may also occur. There is no specific antidote. Treatment consists of discontinuation of terbutaline sulfate injection together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of terbutaline sulfate injection.
Subjects will receive weekly infusion of CRLX101 alone. Starting dose is 12 mg/m\^2 and the next dose level is 15 mg/m\^2 (or 10 mg/m\^2 if 12 mg/m\^2 is not well tolerated. No other dose levels will be explored.
All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
The conventional exercise programme covered a 12-week period, two weekly sessions. The programme aimed at improving aerobic capacity, muscular resistance, balance and flexibility. The program combined land-based and water-based exercise sessions.
This is a prospective, randomized controlled clinical trial. Eighty patients with phlegm and blood stasis block syndrome of ischemic stroke were randomly assigned to Hua Hua reconstruction group or control group at a ratio of 1:1. The treatment period is 12 weeks. The purpose is to evaluate its efficacy and safety, provide an objective basis for precise treatment of traditional Chinese medicine, and improve clinical efficacy. The main result is the changes of NIHSS, Fugl-Meyer, and MAS 90 days after taking the drug. The secondary result is the change in ADL and TCM symptom scale (CM-SS).
Although most cases of myocarditis are self-limiting with a gradual improvement in cardiac function, the involvement of myocarditis in sudden cardiac death among children and young adults remains substantial, with rates of 3-17 % and 8.6-12 %, respectively. Moreover, the risk of developing chronic dilated cardiomyopathy ranges from 21 % to 30 % in all cases confirmed by biopsy. Current therapeutic strategies for myocarditis and its complications range from standard supportive care for heart failure and arrhythmias to etiologically oriented, case-based therapeutic options. For example, immunosuppression is indicated only in certain forms of acute myocarditis with clinical or endomyocardial biopsy evidence of immune checkpoint inhibitor-induced myocarditis and autoimmune diseases, including giant cell myocarditis, eosinophilic myocarditis, vasculitis, or cardiac sarcoidosis. However, our views on myocarditis treatment have changed considerably over the past two decades, thanks to the emergence of regenerative cells/tissues as well as drug and gene delivery systems. Cell-based therapies are now growing in popularity in any field of medicine. Studies evaluating the therapeutic efficacy of different stem cells in the treatment of acute myocarditis and its chronic complications have shown that although the experimental characteristics varied from study to study, in general, these strategies reduced inflammation and myocardial fibrosis while preventing myocarditis-induced systolic dysfunction and adverse remodeling in animal models.
BACKGROUND: Takayasu arteritis (TA) and tuberculosis (TB) share similar histopathological and immunological characteristics. Studies comparing patients with TA with or without active or latent TB infection (LTBI) have revealed some differences in clinical and angiographic profiles. Patient with TA and history of TB exhibited more constitutional symptoms and structural damage to the aorta. This study compared the clinical and radiological features of patients with TA with and without active TB or LTBI.
METHODS: We retrospectively analyzed the data of patients with TA at a public tertiary referral outpatient clinic in northeast Brazil from January 2017 to June 2022. Comparisons of clinical features were made according to the presence of TB.
RESULTS: Fifty patients met the eligibility criteria, and a association with TB was identified in 20 (40%) patients (active TB in six and LTBI in 14). There was a predominance of females, and the average age of patients was 40 years. Weight loss was more common in patients with TA and TB (p = 0.005). No significant intergroup differences were noted in terms of comorbidities, medications, erythrocyte sedimentation rates, or C-reactive protein levels. Significant differences were found in abdominal aortic involvement (25% of patients with TA and TB vs. 11.4% in subjects with TA without TB; p = 0.013). Dilations and aneurysms were significantly more common in patients with TA and TB (p = 0.009 and p = 0.027, respectively).
CONCLUSION: Patients with TA and TB have a higher prevalence of dilatation and aneurysms, most commonly in the abdominal aorta.
The subject's brain neurogenesis promoter of the present invention contains miR-30a, etc. or a vector which is for expressing miR-30a, etc. in the brain nerves of young and elderly subjects. The present invention also provides an agent for improving higher nervous function, an agent for improving memory learning function, a method for promoting brain neurogenesis, a method for improving higher nervous function, and a method for improving memory learning function. In the subject's brain neurogenesis promoter, etc. of the present invention, the subject may be an elderly subject.
OBJECTIVE: Hydrocephalus is a common comorbidity of brain tumors in children that may persist following brain tumor resection. This study aimed to explore perioperative risk factors associated with postoperative ventriculoperitoneal shunt (VPS) placement for tumors located at or adjacent to the CSF circulation pathway.
METHODS: Patients aged 0-18 years with tumors invading or adjacent to the CSF circulation pathways who underwent brain tumor resection between October 2015 and September 2021 were included in this study. The outcome metric was whether patients underwent VPS placement within 6 months of tumor resection. Patients were followed up every 3-6 months after surgery. Demographic and perioperative imaging characteristics, clinical variables, and long-term treatments, including radiotherapy or chemotherapy, were included in the analysis.
RESULTS: Two hundred sixty-five children were included in this study. Of these patients, 38 (14.34%) underwent VPS placement within 6 months of tumor resection. One hundred thirty-two patients (49.81%) presented with preoperative hydrocephalus. Results from the multivariate analysis showed that medulloblastoma (OR 4.15, 95% CI 1.74-9.91, p = 0.001), lateral/third ventricle tumors (OR 4.07, 95% CI 1.33-12.30, p = 0.014), postoperative intraventricular hematoma (OR 3.36, 95% CI 1.53-7.38, p = 0.003), and presence of subdural hygroma in the nonoperated area within 48 hours after tumor resection (OR 2.78, 95% CI 1.15-6.74, p = 0.024) were independent risk factors for postoperative VPS placement.
CONCLUSIONS: Postoperative lateral/third ventricle hematoma and subdural hygroma in the nonoperated area, anatomical location, and tumor histology may be potential risk factors for a postoperative VPS after brain tumor resection.
BACKGROUND: The Subglottic Cysts (SGCs) are a rare cause of respiratory distress in infants. Typical risk factors include male gender, extreme prematurity, gastro-oesophageal reflux and invasive ventilation, the latter being associated with mucosal damage and blockage of the subglottic cysts' ducts. We describe a case of acquired subglottic cysts in a premature infants presented with respiratory distress.
CASE PRESENTATION: A premature male infant was born at 25 weeks + 2 days with a history of monochorionic diamniotic twin pregnancy with twin-to-twin transfusion syndrome. During hospitalization, invasive mechanical ventilation was necessary for a total of 18 days; the patient was discharged at postmenstrual age of 40 weeks + 1 day in good condition. At 43 weeks post-menstrual age, he presented to our department with mixed stridor and worsening of respiratory dynamics. A laryngotracheoscopy evaluation was performed. The exam showed the presence of multiple SGCs causing an almost complete obstruction of the airway. Because of the significant reduction of the airway's patency, the child underwent a tracheotomy and thereafter cysts' removal using cold steel microinstruments. A better airway patency was restored although a slight glottic edema persisted. The histopathology confirmed the benign nature of the lesions. Successive controls showed a completely patent airway and absence of SGCs.
CONCLUSION: In conclusion, SGCs should be considered in preterm infants with respiratory distress previously intubated, which cannot be explained by the most common causes. Early diagnosis and treatment are fundamental to reducing the morbidity and mortality associated with this disease.
PURPOSE:To obtain the titled material capable of eliminating foul breath when applied to the teeth in the oral cavity, by using an olefinic alcohol or its ester and catechins or tannins, etc. as main components, adding an oil, fat, wax, etc. thereto, and forming the mixture in the form of a stick. CONSTITUTION:The objective material can be prepared by using (A) an olefinic alcohol of formula CnH2n-1OH (n is 4-20), e.g. crotyl alcohol, cinnamyl alcohol, citronellol, etc. and/or its ester and (B) at least one kind of catechins, tannins or catechin tannins, as main components, adding (C) an oil, fat, wax, natural resin (e.g. shellac), a higher alcohol (e.g. stearyl alcohol), paraffin, or synthetic polymer (e.g. low-molecular weight PE) to the main components, forming the mixture in the form of a stick, and putting into a push-out container furnished with a removable cap.
PROBLEM TO BE SOLVED: To obtain an anti-itch agent containing extract of Jifushi(dried fruit of Chenopodium scoparia L.) or Mokubetsukon (dried root of Momordica cochinchinensis (Lour.) Spreng.) or momordin I or momordin Ic derived therefrom. SOLUTION: The anti-itch agent contains extract of Jifushi (dried fruit of Chenopodium scoparia L.) or Mokubetsukon (dried root of Momordica cochinchinensis (Lour.) Spreng.) extracted with alcohol or acetone, or momordin I or momordin IIc which is a saponin component and derived therefrom and expressed by the formula as an active ingredient. It is preferable that daily dose of the active ingredient of the anti-itch agent is approximately 1-10mg/kg in the case of the extract of the Jifushi or the Mokubetsukon extracted with alcohol, or approximately 0.1-1mg/kg in the case of the momordin I or the momordin Ic which is a saponin component. The anti-itch agent is useful in treating itch, skin itch, eczema, dermatitis, nettle rash, allergic rhinitis, allergic conjunctivitis, immediate asthmatic etc. The anti-itch agent is useful as an anti-itch agent having both of antiallergic action and anti-inflammatory effect, because the above active ingredient has excellent anti-itch action, antiallergic action and anti-inflammatory effect and hardly exhibits adverse effects.
PURPOSE:To obtain an emulsified type cosmetic, having low skin irritancy, good in preservation stability for a long period and capable of manifesting excellent organoleptic characteristics by combining a trehalose monoester of a fatty acid used as a surfactant with a water-soluble polymer. CONSTITUTION:This emulsifiable type skin cosmetic is obtained by combining one or two or more surfactants selected from trehalose monoesters of a fatty acid (e.g. trehalose monocaprylate or trehalose monononanoate) with a water-soluble polymer (e.g. guar gum or locust bean gum). The content of the trehalose monoester of the fatty acid is 0.1-10wt.% based on the total amount of the cosmetic and that of the water-soluble polymer is 0.01-20wt.% based on the total amount of the cosmetic. The cosmetic assumes beautiful appearance characteristics of fine skin texture. For example, a massaging cream, a cleansing cream, a skin cream, a foundation cream, a makeup base, a hair cream, a massage jelly and a medicated jelly are cited as the cosmetic.
Heart failure is the prevalent complication of acute myocardial infarction. We aim to identify a biomarker for heart failure post-acute myocardial infarction. This observational study includes 1062 and 1043 patients with acute myocardial infarction in the discovery and validation cohorts, respectively. The outcomes are in-hospital and long-term heart failure events. S100A8/A9 is screened out through proteomic analysis, and elevated circulating S100A8/A9 is independently associated with heart failure in discovery and validation cohorts. Furthermore, the predictive value of S100A8/A9 is superior to the traditional biomarkers, and the addition of S100A8/A9 improves the risk estimation using traditional risk factors. We finally report causal effect of S100A8/A9 on heart failure in three independent cohorts using Mendelian randomization approach. Here, we show that S100A8/A9 is a predictor and potentially causal medicator for heart failure post-acute myocardial infarction.
A novel method for the preparation of a highly densified and at least partly, preferably fully or almost fully hydrated ceramic for use in the preparation of a pharmaceutical composition notably for controlled-release of one or more therapeutically, prophylactically and/or diagnostically active substance. The method involves a concomitant step of hydrating and densifying a bioresorbable and hydratable ceramic such as calcium sulphate. The invention also relates to compositions comprising such a highly densified ceramic. The pharmaceutical composition is useful for targeted and controlled local prolonged release of active substances, e.g. anti-cancer agents, whereby the spectrum and severity of side effects are minimized due to an optimized local concentration-time profile. ® KIPO & WIPO 2009
Bupivacaine 0.5%-Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Bupivacaine0.5%. Volume injected is 6 mL/nerve; 12 mL total.
Premature Closure of Fetal Ductus Arteriosus:

Avoid use of NSAIDs, including DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%, in pregnant women at about 30 weeks gestation and later. NSAIDs, including DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment:

Use of NSAIDs, including DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation.

Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% treatment extends beyond 48 hours. Discontinue DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% if oligohydramnios occurs and follow up according to clinical practice [ see Use in Specific Populations (8.1)].
PURPOSE: A synthesized curcuminoid derivative is provided to ensure excellent stability, antioxidation, and anti-cancer effect. CONSTITUTION: A composition with radiosensitization effect contains a compound of chemical formula 1 as an active ingredient. In chemical formula 1, R1 and R2 are OH; and R3 and R4 are H or CH_3O. The radiosensitization effect is sensitization to cancer cells. The cancer cells are skin cancer, gastric cancer, or breast cancer. The radiation is gamma ray. A composition which is more stable than natural curcumin contains the compound of chemical formula 1 as an active ingredient. A pharmaceutical composition for anti-cancer contains the compound of chemical formula 1 as an active ingredient.
PROBLEM TO BE SOLVED: To obtain a dermal pretreatment agent increasing a moisture-keeping effect of a cosmetic liquid by applying on the skin before using the cosmetic liquid and having excellent sensuous property, and excellent in formulation stability by including an oil agent containing a methylphenylpolysiloxane, microorganism-produced polysaccharides and a buffer solution. SOLUTION: This dermal pretreatment agent contains (A) at least one kind of oil agent containing methylphenylpolysiloxane, (B) 0.5-1.5 wt.% of microorganism-produced polysaccharides (e.g. xanthan gum) and (C) a buffer solution, preferably an aqueous solution of a readily soluble salt such as a phosphate of 0.01-3 wt.% concentration. In the pretreatment agent, preferably 0.01-10 wt.% of the component A and 10-95 wt.% of the component C are contained. The objective pretreatment agent can be applied as a medical agent, a quasi-drug, a cosmetic, etc., and can be applied as a formulation of, e.g. latexes, creams, packs, massages, a foundation of makeup, an ultraviolet rays protector, etc.
Then invention relates to a radix bardanae health drink and a method for producing drinks, in particular to a method for producing a radix bardanae drink. The invention is realized by the following technical proposal steps: 1. Selecting the fresh radix bardanae with no mustiness and metamorphism, 2. Using fluid purifying water to rinse clean, 3. Cutting into slices and drying, 4. Extracting, 5. Filtering, 6. Preparing, 7.Antisepticising, 8. Canning; thereby being able to obtain the radix bardanae health drink. The invention has the advantages of uniform color, no impurities, moderate saccharinity and high nutrition value; the invention also has the advantages of specific freshness of the radix bardanae, harmonious taste and no obvious taste of Chinese traditional medicine soup, etc. The radix bardanae health drink produced by the invention is convenient for long period storage, the application and popularization of the radix bardanae and better service for Chinese people.
Uremic toxins (UTs) are microbiota-derived metabolites that accelerate the progression of kidney damage in patients with chronic kidney disease (CKD). One of the major UTs involved in CKD progression is p-cresol-sulfate (PCS), derived from dietary l-tyrosine (l-Tyr). Here, we engineered a probiotic strain of Escherichia coli Nissle 1917, to convert l-Tyr to the nontoxic compound p-coumaric acid via tyrosine ammonia lyase (TAL). First, a small metagenomic library was assessed to identify the TAL with the greatest whole-cell activity. Second, accessory genes implicated in the import of l-Tyr and export of PCA were overexpressed to enhance l-Tyr degradation by 106% and 56%, respectively. Last, random mutagenesis coupled to a novel selection and screening strategy was developed that identified a TAL variant with a 25% increase in whole-cell activity. Taken together, the final strain exhibits a 183% improvement over initial whole-cell activity and provides a promising candidate to degrade l-Tyr mediated PCS accumulation.
PURPOSE: A composition containing a Psoralea corylifolia L. extract or a fraction thereof is provided to suppress NK1 or M3 receptor and to prevent, relieve, or treat diseases or symptom relating to NK1 or M3 receptor. CONSTITUTION: A Psoralea corylifolia L. seed extract suppresses NK1 or M3 receptor. The extract is prepared using alcohol of C1-C4, an alcohol solution of C1-C4, glycerin, butylenes glycol, propylene glycol, methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, dichloromethane, or a mixture thereof. A method for preparing a fraction of the extract comprises a step of adding 60-100 vol% of alcohol solution of C1-C4 to the extract. A pharmaceutical composition for preventing, relieving, or treating irritable bladder syndrome contains the extract or fraction as an active ingredient. [Reference numerals] (AA) Hot water; (BB) Ethanol